Polio vaccine: Is it time for a change?

Archives of Disease in Childhood

Volumn 78, Issue 6, 1998, Pages 571-574

  Finn, Adam ^a   Bell, Frank ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE;

DRUG INDUCED DISEASE; HUMAN; INCIDENCE; INFECTION CONTROL; ORAL DRUG ADMINISTRATION; POLIOMYELITIS; PRIORITY JOURNAL; SHORT SURVEY; VACCINATION;

EID: 0031778809     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.78.6.571     Document Type: Short Survey

References (36)

1. Cochi SL, Hull HF, Sutter RW, Wilfert CM, Katz SM. Commentary: the unfolding story of global poliomyelitis eradication. J Infect Dis 1997;175:S1-3.
2. Eichner M, Dietz K. Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? Am J Epidemiol 1996;143:816-22.
3. Poliomyelitis outbreak - Albania, 1996. MMWR Morb Mortal Wkly Rep 1996;45:819-20.
4. Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis 1976-1995. J Infect Dis 1997;175:S165-72.
5. Paralytic poliomyelitis - United States, 1980-1994. MMWR Morb Mortal Wkly Rep 1997;46:79-83.
6. Salisbury DM, Ramsay ME, White JM, Brown DW. Polio eradication: surveillance implications for the United Kingdom. J Infect Dis 1997;175:S156-9.
7. Minor PD, John A, Ferguson M, Icenogle JP. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccine. J Gen Virol 1986;67:693-706.
8. Kew OM, Nottay BK, Hatch MH, Nakano JH, Obijeski JF. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. J Gen Virol 1981;56: 337-47.
9. Joce R, Wood D, Brown D, Begg N. Paralytic poliomyelitis in England and Wales, 1985-91. BMJ 1992;305:79-82.
10. Nkowane BM, Wassilak SG, Orenstein WA, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 1987;257:1335-40.
11. Sabin AB. Is there a need for a change in poliomyelitis immunization policy? Pediatr Infect Dis J 1987;6:887-9.
12. Salk J, van Wezel AL, Stoeckel P, et al. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis. Dev Biol Stand 1981;47:181-98.
13. Paradiso PR. The future of polio immunization in the United States: are we ready for change? Pediatr Infect Dis J 1996;15:645-9.
14. Plotkin SA. Inactivated polio vaccine for the United States: a missed vaccination opportunity. Pediatr Infect Dis J 1995; 14:835-9.
15. Drucker J. Poliomyelitis in France: epidemiology and vaccination status. Pediatr Infect Dis J 1991;10:967-9.
16. Tulchinsky TH. Combined OPV and IPV program in control of poliomyelitis in two endemic areas - a potential tool in the struggle to eradicate poliomyelitis. Public Health Reviews 1993;21:153-6.
17. Ramsay ME, Begg NT, Gandhi J, Brown D. Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatr Infect Dis J 1994;13:1117-21.
18. Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 1990;162:1291-7.
19. Prevots DR, Sutter RW, Strebel PM, Weibel RE, Cochi SL. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med 1994;148:479-85.
20. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992;14:568-79.
21. Recommended childhood immunization schedule - United States, January-December 1997. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 1997;99:136-7.
22. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46: 1-25.
23. Miller MA, Sutter RW, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA 1996;276:967-71.
24. Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991;163:1-6.
25. Ghendon Y, Robertson SE. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ 1994;72:973-83.
26. Hovi T, Cantell K, Huovilainen A, et al. Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1986;i:1427-32.
27. Slater PE, Orenstein WA, Morag A, et al. Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet 1990;335:1192-5.
28. Conyn van Spaendonck MA, Oostvogel PM, van Loon AM, van Wijngaarden JK, Kromhout D. Circulation of poliovirus during the poliomyelitis outbreak in The Netherlands in 1992-1993. Am J Epidemiol 1996;143:929-35.
29. Schaap GJ, Bijkerk H, Coutinho RA, Kapsenberg JG, van Wezel AL. The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic. Prog Med Virol 1984;29:124-40.
30. Bottiger M, Mellin P, Romanus V, Soderstrom H, Wesslen T, von Zeipel G. Epidemiological events surrounding a paralytic case of poliomyelitis in Sweden. Bull World Health Organ 1979;57:99-103.
31. Chen RT, Hausinger S, Dajani AS, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States. JAMA 1996;275:1639-45.
32. Mallet E, Hoffenbach A, Salomon H, Blondeau C, Fritzell B. Primary immunization with combined, acellular DTaP-IPV-Act-HIB vaccine given at 2-3-4 or 2-4-6 months of age [abstract]. 14th meeting of the European Society for Paediatric Infectious Diseases, 1996.
33. Simoes EA, Padmini B, Steinhoff MC, Jadhav M, John TJ. Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child 1985;139:977-80.
34. Baker JD, Halperin SA, Edwards K, Miller B, Decker M, Stephens D. Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines. J Pediatr 1992;121:523-7.
35. Halperin SA, Langley JM, Eastwood BJ. Effect of inactivated poliovirus vaccine on the antibody response to Bordetella pertussis antigens when combined with diphtheria-pertussis-tetanus vaccine. Clin Infect Dis 1996; 22:59-62.
36. Dagan R, Botujansky C, Watemberg N, et al. Safety and immunogenicity in young infants of Haemophilus b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis-enhanced inactivated poliovirus vaccine. Pediatr Infect Dis J 1994;13:356-62.